Xbrane Biopharma ABs Year End Report for 2016 is now available on the Company’s website, www.xbrane.com.
October – December
- Net sales 532 503 (83 736) SEK
- Net sales growth 536 %
- Total income 2 582 607 (599 747) SEK
- Earnings before tax -10 099 892 (-5 331 005) SEK
- Cash flow from current operations -12 262 437 (-8 980 850) SEK
- Earnings per share -2,12 (-2,39) SEK
January – December
- Net sales 2 490 117 (392 859) SEK
- Net sales growth 534 %
- Total income 4 689 201 (943 326) SEK
- Earnings before tax -33 288 662 (-11 844 786) SEK
- Cash flow from current operations -39 481 391 (-12 386 674) SEK
- Earnings per share -7,00 (-5,18) SEK
Significant events during the fourth quarter
- AIFA inspected the Spherotide production facility with positive results.
- Xbrane received scientific advice regarding the regulatory and clinical strategy for Spherotide from the German Regulatory Authority, BfArM.
- Xbrane signed a non-binding term-sheet with a Chinese pharmaceutical company regarding out-licensing of Spherotide in China.
- Xbrane out-licensed the rights for sales and marketing of Spherotide to BioAvenir in Israel.
- Xbrane appointed Anders P. Wiklund as a strategic advisor.
Significant events after the fourth quarter
- Xbrane received GMP approval of Spherotide production facility in Italy from AIFA (Italian Medicines Agency).
- Xbrane announced positive biosimilarity data on Xlucane.
For further information, please contact:
Martin Åmark, Chief Executive Officer Xbrane Biopharma
Tel: +46 (0) 763-093 777
E-mail: martin.amark@xbrane.com